Search results
Results From The WOW.Com Content Network
FRANKFURT (Reuters) -Novartis has dialled up its sales growth target to 5% per year until 2027, citing demand for innovative drugs after the spin off of its generics business. The medium-term ...
Swiss drugmaker Novartis raised its 2024 earnings guidance for the second time on Thursday, driven by a gain in prescriptions for drugs including heart failure treatment Entresto and arthritis ...
Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care ...
Nilotinib is a Bcr-Abl tyrosine kinase inhibitor and works by interfering with signalling within the cancer cell. [ 5] Nilotinib was approved for medical use in the United States in 2007. [ 5] It is on the World Health Organization's List of Essential Medicines. [ 6] It is approved as a generic medication.
October 30, 2023 at 6:30 AM. By Ludwig Burger. FRANKFURT (Reuters) -Novartis said its experimental drug atrasentan was shown to have a positive effect on an indicator of kidney health in people ...
He spent 8 years working in Novartis Vaccines, at the time a non-profit division focused on developing vaccines for children and patients around the world and served as the Global Head of Development, Novartis Vaccines in the US between 2012 and 2014 before moving to Sandoz as Global Head of Biopharmaceuticals and Oncology Injectables. [6] [17]
The Socialist (Irish newspaper) El Socialista (newspaper) El Sol Latino. Solidarity (newspaper) The Southern Cross (Argentina) Strathclyde Telegraph.
BERLIN (Reuters) -Novartis said on Thursday it has launched a tender offer to acquire MorphoSys, a German developer of cancer treatments, for an aggregate 2.7 billion euros ($2.9 billion).